Advances in pulmonary and pleural malignant disorders
نویسندگان
چکیده
منابع مشابه
Chemotherapy options and new advances in malignant pleural mesothelioma.
Malignant pleural mesothelioma continues to be a challenging clinical problem. While traditionally, chemotherapy has been thought to be of only modest benefit to patients with this disease, novel antineoplastic agents and combination regimens incorporating these agents are gradually changing this perception. Early attempts at treatment and palliation with single agents such as doxorubicin met w...
متن کاملTh1 and Th2 Cytokine Profiles in Malignant Pleural Effusion
Background: The alteration of Th1 and Th2 cytokine levels is the subject of controversy in pleural effusions caused by malignancy, a situation that favors a Th2 immune response. Objective: To examine the different levels of IL-4 and IL-10 (Th2 cytokines), and IL-2 and interferon-γ (IFN-γ) (Th1 cytokines) in malignant and non-malignant pleural effusions. Method: The cytokine levels in pleural fl...
متن کاملTenascin Expression and Distribution in Pulmonary and Pleural Fibrotic Disorders
Fibrotic pulmonary and pleural disorders represent a group of intrathoracic disorders with different etiologies and prognoses. A prominent part of both pulmonary and pleural fibrotic disorders remains etiologically unknown. An essential feature for all these disorders is an increase and disarray of many extracellular matrix proteins which take part in the remodeling of the fibrotic tissue. Furt...
متن کاملMolecular profiling of malignant pleural mesothelioma and pulmonary fibrosis
.........................................................................................................................5 I REVIEW OF THE LITERATURE...................................................................................8 1 ASBESTOS FIBRES .........................................................................................................8 1.1.1 Oxidative stress and antioxidant...
متن کاملAdvances in pleural disease.
The burden of pleural disease continues to increase internationally leading to significant healthcare costs and an urgent need for improving management. Pleural effusion is a common presentation for many pulmonary and systemic diseases, and it is estimated that each year 1.5 million people develop a pleural effusion in the USA and 200000–250000 in the UK [1, 2]. Despite the prevalence of pleura...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Medicine
سال: 2019
ISSN: 1470-2118,1473-4893
DOI: 10.7861/clinmedicine.19-3-234